Oxyphilic Adenoma (Hurthle Cell Tumor) – A Complete Medical Guide
Overview
Oxyphilic adenoma, more commonly referred to as a Hurthle cell tumor (HCT), is a neoplasm that originates from the follicular cells of the thyroid gland. These cells are called “oxyphilic” or “Hurthle cells” because they contain abundant, granular, eosinophilic (pink‑staining) cytoplasm that is rich in mitochondria.
Hurthle cell tumors are classified into three categories based on their behavior:
- Hurthle cell adenoma (HCA) – a benign, non‑cancerous tumor.
- Hurthle cell carcinoma (HCC) – a malignant tumor that can spread beyond the thyroid.
- Hurthle cell tumor of uncertain malignant potential (HUT‑UMP) – an intermediate lesion where the pathology cannot definitively label it benign or malignant.
Who is affected?
HCTs are most often diagnosed in adults between the ages of 40 and 60, with a slight female predominance (approximately 3 : 1 women to men). However, they can occur at any age, including in children and the elderly.
Prevalence
Overall thyroid nodules are found in up to 68 % of the adult population on ultrasound, but only about 3‑5 % of those nodules represent Hurthle cell neoplasms. Of these, the majority (≈80 %) are benign adenomas, while the remaining 20 % are malignant or of uncertain potential.1
Symptoms
Many Hurthle cell tumors are discovered incidentally during imaging for unrelated reasons because they often grow slowly and cause few early symptoms. When symptoms do appear, they usually relate to the size of the nodule or, in the case of carcinoma, to local invasion or metastasis.
- Neck mass or swelling – a palpable lump in the front of the neck, often painless.
- Hoarseness or voice changes – may occur if the tumor compresses the recurrent laryngeal nerve.
- Difficulty swallowing (dysphagia) – especially with larger nodules that press on the esophagus.
- Shortness of breath or choking sensation – rare, caused by tracheal compression.
- Pain or tenderness in the neck – uncommon, may suggest rapid growth or inflammation.
- Symptoms of thyroid hormone excess or deficiency – most Hurthle cell adenomas are “non‑functioning,” but a small subset can produce thyroid hormone (hyperthyroidism) or, rarely, cause hypothyroidism after surgery.
- Rapid enlargement – especially worrisome for malignancy.
- Regional lymph node enlargement – may indicate metastatic spread in carcinoma.
Causes and Risk Factors
The exact cause of Hurthle cell tumors is unknown, but several factors appear to increase risk:
Genetic and molecular factors
- Mutations in the NRG1 and AKT1 pathways have been identified in some HCTs.
- Familial non‑medullary thyroid cancer syndromes (e.g., PTEN hamartoma tumor syndrome) can predispose to Hurthle cell neoplasms.
Demographic and environmental factors
- Age ≥ 40 years – risk rises with advancing age.
- Female sex – hormonal influences may play a role.
- Radiation exposure – prior therapeutic or occupational radiation to the head and neck increases the likelihood of thyroid tumors, including HCTs.2
- Iodine deficiency – historically linked to follicular thyroid cancers, which share a lineage with Hurthle cell tumors.
Other possible associations
- Autoimmune thyroiditis (Hashimoto’s disease) – chronic inflammation may promote Hurthle cell change.
- Family history of thyroid cancer – a modest risk factor.
Diagnosis
Diagnosing a Hurthle cell tumor involves a step‑wise approach that integrates clinical evaluation, imaging, and pathology.
1. Physical examination
The clinician assesses the thyroid size, consistency, and any cervical lymphadenopathy.
2. Blood tests
- Thyroid‑stimulating hormone (TSH) – to determine whether the nodule is functioning.
- Free T4 and T3 – to assess hormone production.
- Serum calcitonin (if medullary thyroid cancer is a consideration).
3. Neck ultrasound
High‑resolution ultrasound is the first‑line imaging test. Features that raise suspicion for malignancy include:
- Hypoechoic texture
- Irregular margins
- Micro‑calcifications
- Increased central vascularity
- Presence of suspicious cervical lymph nodes
4. Fine‑needle aspiration (FNA) biopsy
Using a thin needle, cells are aspirated from the nodule and examined cytologically. The Bethesda System categorizes results; a “Hurthle cell‑predominant” aspirate falls into Bethesda III (Atypia of undetermined significance) or IV (Follicular neoplasm/suspected Hürthle cell tumor). Because cytology cannot reliably distinguish adenoma from carcinoma, additional steps are needed.
5. Molecular testing (optional)
Testing for mutations (e.g., RAS, PAX8‑PPARG) may help stratify cancer risk, although the utility in HCT is still under investigation.
6. Surgical histopathology
The definitive diagnosis is made after the nodule is removed (usually via thyroid lobectomy). Pathologists evaluate capsular and vascular invasion:
- No invasion → Hurthle cell adenoma (benign).
- Invasion present → Hurthle cell carcinoma.
- Unclear or minimal features → HUT‑UMP.
7. Staging (for carcinoma)
If cancer is confirmed, further imaging (CT, MRI, or ^131I‑whole‑body scan) assesses local spread and distant metastases, following the AJCC/TNM staging system.
Treatment Options
Treatment is tailored to the tumor’s size, pathology, and the patient’s overall health.
1. Surgery
- Lobectomy (hemithyroidectomy) – removal of the affected thyroid lobe; standard for presumed benign adenoma and many HUT‑UMPs.
- Total thyroidectomy – recommended for confirmed Hurthle cell carcinoma, large tumors (>4 cm), or bilateral disease.
- Selective central neck dissection may be performed if suspicious lymph nodes are identified.
2. Radioactive iodine (RAI) therapy
Effective for many differentiated thyroid cancers, but Hurthle cell carcinoma often shows reduced iodine uptake. RAI is considered when the tumor demonstrates significant uptake on a diagnostic scan.
3. Thyroid hormone suppression
After surgery, patients are typically placed on levothyroxine to maintain low TSH levels, which can reduce the risk of recurrent disease in carcinoma cases.
4. Targeted systemic therapies (advanced/metastatic disease)
- Tyrosine‑kinase inhibitors (TKIs) such as lenvatinib or sorafenib – approved for radioactive‑iodine‑refractory differentiated thyroid cancer, including HCC.
- Clinical trials exploring novel agents (e.g., selpercatinib) are ongoing.
5. Radiation therapy
External‑beam radiation may be considered for unresectable disease, incomplete resection, or symptomatic bone metastases.
6. Lifestyle and supportive measures
- Calcium and vitamin D supplementation after total thyroidectomy to prevent hypocalcemia.
- Regular follow‑up with neck ultrasound and serum thyroglobulin (for carcinoma) to detect recurrence.
Living with Oxyphilic Adenoma (Hurthle Cell Tumor)
Even after successful treatment, most patients benefit from a structured follow‑up plan and lifestyle adjustments.
Follow‑up schedule
- Benign adenoma – neck ultrasound at 6–12 months post‑surgery, then every 2‑3 years if stable.
- Carcinoma – neck ultrasound and serum thyroglobulin every 6–12 months for the first 5 years, then annually.
Medication adherence
Take levothyroxine exactly as prescribed, preferably on an empty stomach, and have TSH checked every 6–12 months.
Diet and nutrition
- Maintain adequate iodine intake (≈150 µg/day) through iodized salt or dairy; avoid excessive iodine supplements unless directed by a physician.
- Balanced diet rich in fruits, vegetables, whole grains, and lean protein supports overall health.
Exercise and weight management
Regular aerobic activity (150 minutes per week) helps maintain a healthy weight, which may lower the risk of postoperative complications and improve quality of life.
Psychosocial support
Living with a thyroid tumor can be anxiety‑provoking. Consider counseling, thyroid cancer support groups, or online communities.
Prevention
Because many risk factors are non‑modifiable (age, sex, genetics), prevention focuses on reducing known environmental contributors and promoting early detection.
- Avoid unnecessary radiation – limit exposure to diagnostic head‑neck CT scans when possible; use shielding.
- Maintain adequate iodine intake – especially in regions with historically low dietary iodine.
- Regular neck examinations – people with a family history of thyroid disease should have periodic clinical exams.
- Early evaluation of thyroid nodules – prompt ultrasound and, if indicated, FNA for any palpable or incidentally discovered nodule.
- Healthy lifestyle (smoking cessation, balanced diet, exercise) may lower overall cancer risk.
Complications
If a Hurthle cell tumor is left untreated or incompletely treated, several complications can arise:
- Local airway or esophageal compression – large tumors may cause breathing difficulty or dysphagia.
- Recurrent laryngeal nerve injury – can lead to persistent hoarseness or vocal cord paralysis.
- Hypocalcemia – from inadvertent removal or damage to the parathyroid glands during surgery.
- Metastatic disease – Hurthle cell carcinoma can spread to cervical lymph nodes, lungs, or bone.
- Secondary malignancies – rare but reported after high cumulative doses of radioactive iodine.
- Psychological distress – anxiety, depression, or decreased quality of life related to cancer diagnosis.
When to Seek Emergency Care
- Sudden, severe neck swelling that makes breathing difficult.
- Rapid onset of hoarseness or loss of voice accompanied by coughing or choking.
- Severe, unexplained pain in the neck or throat that does not improve with rest.
- Difficulty swallowing liquids or foods that progresses quickly.
- Signs of severe hyperthyroidism (palpitations, tremor, high fever, confusion).
- Uncontrolled bleeding from a surgical wound after thyroid surgery.
References:
- Mayo Clinic. “Hurthle cell thyroid cancer.” Updated 2023. https://www.mayoclinic.org/
- American Thyroid Association. “Guidelines for Diagnosis and Management of Thyroid Nodules.” 2022. https://www.thyroid.org/
- National Cancer Institute. “Thyroid Cancer Treatment (PDQ®) – Health Professional Version.” 2024. https://www.cancer.gov/
- Cleveland Clinic. “Hurthle Cell Tumor.” 2023. https://my.clevelandclinic.org/
- World Health Organization. “Iodine Deficiency.” 2021. https://www.who.int/